Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Zacks Equity Research

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals

Zacks Equity Research

Will Moderna Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Moderna.

Zacks Equity Research

Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio

by Zacks Equity Research

The biotech sector was in focus with pipeline updates from a few small biotech companies.

Zacks Equity Research

4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large

by Zacks Equity Research

Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus

Zacks Equity Research

Moderna (MRNA) Beats Earnings Estimates in Q4, Revenues Miss

by Zacks Equity Research

Moderna (MRNA) reports narrower-than expected loss in the fourth quarter. However, revenues miss estimates. Stock up.

Zacks Equity Research

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Progress of its pipeline candidates is likely to have increased Moderna's (MRNA) operating expenses in the fourth quarter.

Kinjel Shah headshot

What's in Store for Vertex in 2020 After a Remarkable 2019?

by Kinjel Shah

In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.